Salarius Pharmaceuticals: Funding, Investors & Team (Nov 2026)
Salarius Pharmaceuticals is an emerging biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. The lead compound Seclidemstat represents a potential paradigm shift in the treatment of cancer and we are initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available.
Salarius Pharmaceuticals has raised $8.3M across 2 funding rounds on record, the most recent an undisclosed round of $6.0M announced in May 2023.
That round is below the $8.9M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Salarius Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: May 2023.
Salarius Pharmaceuticals Funding Rounds
Salarius Pharmaceuticals raised $2.3M in a Post-IPO Equity announced in Apr 2022.
1.1 years later, an undisclosed round of $6.0M was announced in May 2023.
Salarius Pharmaceuticals Founders and Leadership Team
Contact details for the Salarius Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Salarius Pharmaceuticals Funding Compared to Other Biotechnology Startups
Salarius Pharmaceuticals' latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Salarius Pharmaceuticals in Biotechnology and Houston
Companies Similar to Salarius Pharmaceuticals
Araceli Biosciences specializes in creating scientific instruments for discovering tissue- and cell-based…
Switchpoint Bio is a biotechnology company that offers immune relevant drug treatments.
Nanopath Inc. is a company that specializes in molecular diagnostics and allows for fast, high-quality…
Frontier Bio is creating lab-grown human tissues as an ethical replacement for animal studies and is setting…
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel…
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…
Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Salarius Pharmaceuticals Funding FAQs
What does Salarius Pharmaceuticals do?
Salarius Pharmaceuticals is an emerging biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. The lead compound Seclidemstat represents a potential paradigm shift in the treatment of cancer and we are initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available.
How much funding has Salarius Pharmaceuticals raised?
Salarius Pharmaceuticals has raised $8.3M across 2 rounds on record. The most recent is an undisclosed round of $6.0M announced in May 2023.
When did Salarius Pharmaceuticals last raise funding?
Salarius Pharmaceuticals' most recent funding round on record is an undisclosed round of $6.0M, announced in May 2023.
Who is the CEO of Salarius Pharmaceuticals?
David Arthur is listed as CEO at Salarius Pharmaceuticals.
Where is Salarius Pharmaceuticals headquartered?
Salarius Pharmaceuticals is based in Houston, Texas, United States.
How many employees does Salarius Pharmaceuticals have?
Salarius Pharmaceuticals is in the 11-50 employee band.
How does Salarius Pharmaceuticals' funding compare to other Biotechnology startups?
Salarius Pharmaceuticals' latest round of $6.0M is below the $8.9M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's Salarius Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Salarius Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.